Protocol Ledger

NCT07284472 · Phase II/III · RECRUITING

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Interventional Phase II/III clinical trial protocol NCT07284472 sponsored by Exciva in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-02 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07284472
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07284472
Protocol FieldVerified Registry Value
NCT IdentifierNCT07284472
Consolidated Lead SponsorExciva
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2026-02-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07284472
Hospital Research SiteLocationSite Profile
Oregon Health and Science University Knight Cancer InstitutePortland, OROpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI